These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8467821

  • 1. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
    Pizzolato G, Chierichetti F, Rossato A, Briani C, Dam M, Borsato N, Saitta B, Zanco P, Ferlin G, Battistin L.
    Eur Neurol; 1993; 33(2):143-8. PubMed ID: 8467821
    [Abstract] [Full Text] [Related]

  • 2. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G, Chierichetti F, Rossato A, Cagnin A, Fabbri M, Dam M, Ferlin G, Battistin L.
    J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB, Bartenstein P, Schober O, Oberwittler C, Lerch H, Masur H.
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
    Schwarz J, Oertel WH, Tatsch K.
    J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
    [Abstract] [Full Text] [Related]

  • 7. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
    Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH.
    Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
    [Abstract] [Full Text] [Related]

  • 8. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC.
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [Abstract] [Full Text] [Related]

  • 9. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K, Schwarz J, Oertel WH, Kirsch CM.
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [Abstract] [Full Text] [Related]

  • 10. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J, Cordes M, Schelosky L, Barzen G, Poewe W, Henkes H, Keske U, Horowski R, Felix R.
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [Abstract] [Full Text] [Related]

  • 11. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy.
    Hertel A, Weppner M, Baas H, Schreiner M, Maul FD, Baum RP, Fischer PA, Hör G.
    Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546
    [Abstract] [Full Text] [Related]

  • 12. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL.
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [Abstract] [Full Text] [Related]

  • 13. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
    Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH.
    Neurology; 1992 Mar; 42(3 Pt 1):556-61. PubMed ID: 1549216
    [Abstract] [Full Text] [Related]

  • 14. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.
    Seppi K, Schocke MF, Donnemiller E, Esterhammer R, Kremser C, Scherfler C, Diem A, Jaschke W, Wenning GK, Poewe W.
    Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073
    [Abstract] [Full Text] [Related]

  • 15. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
    Pizzolato G, Cagnin A, Rossato A, Chierichetti F, Fabbri M, Dam M, Ferlin G, Battistin L.
    Adv Neurol; 1996 Dec; 69():467-73. PubMed ID: 8615167
    [No Abstract] [Full Text] [Related]

  • 16. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW.
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [Abstract] [Full Text] [Related]

  • 17. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Künig G, Oertel WH.
    Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
    [Abstract] [Full Text] [Related]

  • 18. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M, Henkes H, Laudahn D, Bräu H, Kramp W, Girke W, Hierholzer J, Eichstädt H, Felix R.
    Eur J Radiol; 1991 Jan; 12(3):182-6. PubMed ID: 1830273
    [Abstract] [Full Text] [Related]

  • 19. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
    Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G.
    Eur Neurol; 2002 Jan; 47(2):113-7. PubMed ID: 11844900
    [Abstract] [Full Text] [Related]

  • 20. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.